Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

53.55USD
24 Apr 2017
Change (% chg)

$0.07 (+0.13%)
Prev Close
$53.48
Open
$53.85
Day's High
$54.00
Day's Low
$53.51
Volume
8,753,421
Avg. Vol
11,532,175
52-wk High
$77.12
52-wk Low
$46.01

BMY

Chart for BMY

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $88,108.31
Shares Outstanding(Mil.): 1,647.50
Dividend: 0.39
Yield (%): 2.92

Financials

  BMY Industry Sector
P/E (TTM): 20.13 29.08 29.95
EPS (TTM): 2.66 -- --
ROI: 18.67 13.66 13.21
ROE: 29.28 14.61 14.38

Bristol-Myers NASH drug reduces liver fat in midstage study

Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Apr 22 2017

Bristol-Myers NASH drug reduces liver fat in midstage study

April 22 Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Apr 22 2017

BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

* Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

Apr 21 2017

Analysis -As AstraZeneca chases rivals, immuno-oncology gets complicated

LONDON Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.

Apr 19 2017

As AstraZeneca chases rivals, immuno-oncology gets complicated

LONDON Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.

Apr 19 2017

BRIEF-Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology

* Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology

Apr 17 2017

Bristol-Myers to license two drugs to Biogen, Roche

Bristol-Myers Squibb Co said on Thursday it would license two of its drugs to Biogen Inc and Roche Holding AG for an upfront fee of $470 million.

Apr 13 2017

UPDATE 2-Bristol-Myers to license two drugs to Biogen, Roche

* Deals come amid activist investor pressure (Adds background on activist investor pressure)

Apr 13 2017

BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb

* Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168

Apr 13 2017

Bristol-Myers to license two of its drugs to Biogen, Roche

April 13 Bristol-Myers Squibb Co said on Thursday it entered into a deal with Biogen Inc and Roche Holding AG to license two of its drugs for an upfront fee of $470 million.

Apr 13 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.89 +1.13
Pfizer Inc. (PFE.N) $33.74 +0.10
Merck & Co., Inc. (MRK.N) $62.14 +0.25
Sanofi SA (SASY.PA) €84.84 +2.48
AstraZeneca plc (AZN.L) 4,662.50 +96.50
GlaxoSmithKline plc (GSK.L) 1,585.00 +19.50
Eli Lilly and Co (LLY.N) $83.42 +1.53
Roche Holding Ltd. (ROG.S) CHF255.00 +3.30
Roche Holding Ltd. (RO.S) CHF255.25 +2.75

Earnings vs. Estimates